INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025

Rhea-AI Summary

International Isotopes (OTCQB: INIS) reported improved financial results for Q2 and H1 2025. Product sales increased 15.3% to $3.66M in Q2 and 13.5% to $6.89M in H1 2025. The company reduced its net loss by 27% to $160,785 in Q2 and by 29.4% to $273,479 in H1 2025.

Performance highlights include 99% growth in Nuclear Medicine Standards revenue to $2.34M, driven by resolving the Cobalt-57 isotope shortage. Theranostics Products revenue declined 9% to $3.69M due to customer losses. The company received FDA approval for an additional raw material supplier and launched a new Medical Devices segment generating initial revenue of $58,089.

Positive

• Product sales grew 15.3% in Q2 and 13.5% in H1 2025
• Nuclear Medicine Standards revenue increased 99% to $2.34M
• Net loss improved by 29.4% in H1 2025
• FDA approval received for additional raw material supplier
• Successfully launched new Medical Devices segment with initial revenue of $58,089
• Company remains the only domestic US manufacturer of high activity Cobalt-60 sealed-source products

Negative

• Theranostics Products revenue decreased 9% to $3.69M due to loss of standing order customers
• Cobalt Products revenue declined 9% to $750,465
• Ongoing global shortage of Gd-153 affecting BM53 line sources production
• Company still operating at a net loss of $273,479 in H1 2025

• Sale of product for the first six months of 2025 increased 13.5% or $820,529 
• Net Income (Loss) the first six months of 2025 improved 29% to a loss of $273,479
• Non-GAAP EBITDA⁽¹⁾ the first six months of 2025 improved 151% or $142,091

IDAHO FALLS, Idaho, Aug. 13, 2025 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") is pleased to announce its financial results for the second quarter and six months ended June 30, 2025. Revenue from the sale of product for the second quarter of 2025 was $3,655,320, an increase of $486,087 or 15.3%, compared to the same period in the prior year, and for the six months ended June 30, 2025 was $6,894,220, an increase of $820,529 or 13.5% from the same period in the prior year. Net loss for the second quarter of 2025 improved to $160,785 from a loss of $233,445 in the same period last year, a 27% increase, and for the first six months of 2025 improved to $273,479, a 29.4% improvement from the same period in the prior year. Non-GAAP EBITDA⁽¹⁾ increased to $1,199 in the second quarter of 2025, an increase of $85,202, and non-GAAP EBITDA⁽¹⁾ for the first six months of 2025 improved to $51,569, a 157% improvement from the same period in the prior year. The Company also reported a non-GAAP adjusted EBITDA⁽¹⁾ of $39,114 for the second quarter of 2025 and $174,020 for the first six months of 2025.

Increases for the six months ended June 30, 2025 were driven primarily by growth of sales of Nuclear Medicine Standards products and Cobalt product sales, partially offset by a decrease in sales of Theranostics products compared to the same period in the prior year.

(1) See "Non-GAAP Financial Measures" below.

Shahe Bagerdjian, President & CEO of the Company, said, "We are happy with our growth of sales, ending this quarter with a 15% increase and 13.5% growth for the first half compared to last year. We still anticipate a solid 2^nd half of 2025 due to increased seasonal sales of Cobalt products, and the launch of new products. "

Segment Results 

Theranostics Products
Revenue from the sale of Theranostics Products for the first six months of 2025 was $3,692,233, compared to $4,074,213 for the same period in the prior year. This is a decrease of $381,757 or 9% compared to the same period in the prior year, primarily due to a loss of some standing order customers. In the second quarter of 2025, the Company received US FDA approval to add an additional raw material supplier. We continue to see demand for generic sodium iodide I-131 pharmaceutical and I-131 theranostic API products, which are used in radiolabeling third party drug products.

Nuclear Medicine Standards
Revenue from the sale of Nuclear Medicine Standards products for the first six months of 2025 was $2,340,580, compared to $1,173,311 for the same period in the prior year. This represents an increase of $1,167,269 or 99%, compared to the same period in the prior year, primarily due to remedying of the global shortage of Cobalt-57 isotope, which lasted from January 2024 to late July 2024. Additionally, our Nuclear Medicine Standards segment continues to be impacted by an on-going global outage of Gd-153, which is the raw material in the Company's key products, BM53 line sources. We expect full year 2025 revenues in this segment to reflect historically normal amounts as the supply chain has normalized, and we continue to launch new products under our RadQual and PhanQual brands.

Cobalt Products
Revenue from the sale of Cobalt Products for the first six months of 2025 was $750,465, compared to $826,167 for the same period in the prior year. This represents a decrease of $75,702 or 9%, compared to the same period in the prior year, primarily due to timing of sales over the course of the last 12 months. Large value sales of high activity Cobalt-60 sources are seasonal and occur at various times throughout the year. Frequently the timing of these sales can have a significant impact on period comparisons. Fiscal 2024 marked a historical high in Cobalt Product sales for the Company. The Company remains the only domestic United States manufacturer of high activity Cobalt-60 sealed-source products. We anticipate sales of Cobalt products for the rest of 2025 to be strong based on planned production and sales in the third quarter of 2025.

Medical Devices 
Revenue from the sale of Medical Device products for the first six months of 2025 was $58,089, compared to no sales for the same period in the prior year. Medical Devices was a new reportable business segment for fiscal year 2024. We have invested in this segment throughout the past three years and anticipate additional investments in the rest of 2025 as we ramp to commercialization of products. This segment includes The Swirler® and Tru-Fit™ Mouthpiece, Xenon System, and related accessories under the RadVent brand as well as partnering with leading manufacturers for distribution through our network of global distributors. Additionally, the Company invested in a joint venture arrangement for our EasyFill Automated Iodine Capsule System, which recently signed an exclusive distribution and servicing agreement for the full line of Scintomics ATT products. The Medical Device segment is focused on bringing products to market which help the industry improve safety, efficiency, and patient access to radiopharmaceutical diagnostics and therapeutics. 

	Three Months Ended June 30, 2025								Six Months Ended June 30, 2025
	2025		2024		$ Change		% Change		2025		2024		$ Change		% Change
Sale of product	$	3,655,320	$	3,169,233	$	486,087	15.3 %		$	6,894,220	$	6,073,691	$	820,529	13.5 %
Gross profit	$	2,141,559	$	2,017,511	$	124,048	6.1 %		$	4,173,596	$	3,883,622	$	289,974	7.5 %
Total Operating Expense	$	2,276,400	$	2,197,635	$	78,765	3.6 %		$	4,373,453	$	4,329,942	$	43,511	1.0 %
Operating Profit (Loss) Before Other Exp	$	(134,841)	$	(180,124)	$	45,283	25.1 %		$	(199,857)	$	(446,320)	$	246,463	55.2 %
Other Income (Expense)	$	(25,944)	$	(52,321)	$	27,377	51 %		$	(73,622)	$	58,824	$	(132,466)	225 %
Net Income (Loss)	$	(160,785)	$	(233,445)	$	72,660	31.1 %		$	(273,479)	$	(387,496)	$	114,017	29.4 %
Net income per common share – basic:	$	—	$	—	$	—			$	—	$	—	$	—
Net income per common share – diluted:	$	—	$	—	$	—			$	—	$	—	$	—
Weighted avg. shares outstanding - basic		527,355,415		522,779,643						525,718,720		521,473,413
Weighted avg. shares outstanding - diluted		527,355,415		522,779,643						525,718,720		521,473,413

Full Earnings Release Available on INIS Website
A full version of this earnings release is available on our Investor Center website at https://intisoid.com/investor-center/.

Non-GAAP Financial Measures
This press release contains financial measures that do not comply with U.S. generally accepted accounting principles ("GAAP"), such as EBITDA and Adjusted EBITDA. EBITDA is defined as net income plus interest, income taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA, adjusted to exclude items that are deemed to be unusual and non-recurring, and that we do not believe are indicative of the companies recurring operating performance, such as non-cash stock-based compensation, gain on disposal of assets, and costs associated with NRC enforcement matters and our medical devices buildout.

These non-GAAP financial measures are supplemental measures to our results of operations as reported under GAAP. Our management uses these measures to better analyze our financial results and business operations. In management's opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the ongoing operating performance of the Company and its future outlook. Such measures should not be considered alternatives to net income or any other performance measures derived in accordance with GAAP. The Company's measurement of EBITDA and Adjusted EBITDA may not be comparable to similar measures of other companies as they are not performance measures calculated in accordance with GAAP.

Non-GAAP Reconciliations
	Three Months Ended June 30, 2025								Six Months Ended June 30, 2025
	2025		2024		$ Change		% Change		2025		2024		$ Change		% Change
Net income (loss)	$	(160,785)	$	(233,445)	$	72,660	31 %		$	(273,479)	$	(387,496)	$	114,017	29 %
Interest expense, net	$	64,039	$	47,977	$	16,062	-33 %		$	126,066	$	96,552	$	29,514	-31 %
Provision for income taxes	$	0	$	0	$	—	—		$	0	$	0	$	—	—
Depreciation and amortization	$	97,945	$	101,447	$	(3,502)	-3 %		$	198,982	$	200,422	$	(1,440)	-1 %
EBITDA	$	1,199	$	(84,021)	$	85,220	101 %		$	51,569	$	(90,522)	$	142,091	157 %
Non-cash stock-based compensation	$	(4,482)	$	21,750	$	(26,232)	-121 %		$	65,797	$	84,400	$	(18,603)	-22 %
Gain on disposal of property, plant, and equipment	$	0	$	(13,492)	$	—	—		$	0	$	(13,492)	$	—	—
NRC Enforcement Matters(a)(1)	$	30,087	$	157,325	$	(76,527)	-100 %		$	30,087	$	233,852	$	(76,527)	-100 %
Medical Devices Buildout(b)(1)	$	12,310	$	55,805	$	(43,495)	-78 %		$	26,567	$	138,801	$	(112,234)	-81 %
Adjusted EBITDA	$	39,114	$	137,367	$	(98,253)	-72 %		$	174,020	$	353,039	$	(179,019)	-51 %
(a) Represents costs for an NRC violation that occurred in 2022, including legal expenses, costs for corrective actions, and NRC fines
(b) Represents legal work for initial buildout of the Medical Devices business segment

International Isotopes Inc. Safe Harbor Statement 
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2024. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward- looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

About International Isotopes Inc.
International Isotopes Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. INIS manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. INIS manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. The Company also manufactures Cobalt-60 sealed source products and provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. INIS recently launched a manufacturing joint venture with Alpha Nuclides, to bring INIS and RadQual products into China via Radnostix China. The Company is working to launch its RadVent brand of medical devices in 2025, which includes the Swirler® and Tru-Fit™ product lines. For more information, visit intisoid.com.

International Isotopes Contact: admin@intisoid.com radnostix.com intisoid.com 208.524.5300

Investor Relations Contact: David Drewitz, Creative Options Communications Investor and Public Relations david@creativeoptionscommunications.com www.creativeoptionsmaketing.com 972.814.5723

 

View original content:https://www.prnewswire.com/news-releases/international-isotopes-inc-announces-fiscal-results-for-the-second-quarter-and-six-months-ended-june-30-2025-302528549.html

SOURCE International Isotopes Inc.

FAQ

What were International Isotopes (INIS) Q2 2025 earnings results?

INIS reported Q2 2025 revenue of $3.66M, up 15.3% year-over-year, with a reduced net loss of $160,785, a 27% improvement from the previous year.

How much did INIS sales grow in the first half of 2025?

INIS product sales increased 13.5% to $6.89M in the first half of 2025 compared to the same period in 2024.

What is driving growth for International Isotopes in 2025?

Growth is primarily driven by a 99% increase in Nuclear Medicine Standards revenue due to resolving the Cobalt-57 isotope shortage, and the launch of new products under RadQual and PhanQual brands.

What segments showed declining performance for INIS in H1 2025?

Both Theranostics Products and Cobalt Products segments declined 9% year-over-year, with Theranostics revenue at $3.69M and Cobalt Products at $750,465.

What new developments did INIS announce for 2025?

INIS received FDA approval for a new raw material supplier, launched a new Medical Devices segment, and established a manufacturing joint venture with Alpha Nuclides for the Chinese market.